中文速读
针对肾小球肾炎,使用大鼠模型和肾小球系膜细胞,通过Entranster-in vivo递送TGFβ1-siRNA,结合地塞米松,实现抗炎/抗纤维化双重调控,改善肾脏病理。
大鼠尾静脉肾siRNAmesangial
Dual-Regulated Functionalized Liposome-Nanoparticle Hybrids Loaded with Dexamethasone/TGFβ1-siRNA for Targeted Therapy of Glomerulonephritis
Affiliations
- 1 College of Pharmacy, Southwest Minzu University, Chengdu 610041, Sichuan, PR China.
- 2 Lab of Pharmaceutics, School of Pharmaceutical Sciences, Sun Yat-Sen University, Guangzhou 510006, PR China.
- 3 Key Laboratory of Advanced Technologies of Materials Ministry of Education, School of Materials Science and Engineering, Southwest Jiaotong University, Chengdu 610031, PR China.
- 4 College of Animal & Veterinary Sciences, Southwest Minzu University, Chengdu 610041, Sichuan, PR China.
- 5 Officers College of PAP, Chengdu 610213, Sichuan, PR China.
- PMID: 34968038
- DOI: 10.1021/acsami.1c20053
Abstract
Mesangial cell (MC)-mediated glomerulonephritis is a frequent cause of end-stage renal disease, with immune inflammatory damage and fibrosis as its basic pathological processes. However, the treatment of glomerulonephritis remains challenging owing to limited drug accumulation and serious side effects. Hence, the specific codelivery of “anti-inflammatory/antifibrosis” drugs to the glomerular MC region is expected to yield better therapeutic effects. In this study, liposome-nanoparticle hybrids (Au-LNHy) were formed by coating the surface of gold nanoparticles with a phospholipid bilayer; the Au-LNHys formed were comodified with PEG and α8 integrin antibodies to obtain gold nanoparticle immunoliposomes (Au-ILs). Next, the Au-ILs were loaded with dexamethasone and TGFβ1 siRNA to obtain DXMS/siRNA@Au-ILs. Our results showed that the functionalized nanoparticles had a core-shell structure, a uniform and suitable particle size, low cytotoxicity, and good MC entry, and lysosomal escape abilities. The nanoparticles were found to exhibit enhanced retention in glomerular MCs due to anti-α8 integrin antibody mediation. In vivo and in vitro pharmacodynamic studies showed the enhanced efficacy of DXMS/siRNA@Au-ILs modified with α8 integrin antibodies in the treatment of glomerulonephritis. In addition, DXMS/siRNA@Au-ILs were capable of effectively reducing the expression levels of TNF-α, TGF-β1, and other cytokines, thereby improving pathological inflammatory and fibrotic conditions in the kidney, and significantly mediating the dual regulation of inflammation and fibrosis. In summary, our results demonstrated that effectively targeting the MCs of the glomerulus for drug delivery can inhibit local inflammation and fibrosis and produce better therapeutic effects, providing a new strategy and promising therapeutic approach for the development of targeted therapies for glomerular diseases.
Keywords: anti-inflammatory; antifibrosis; functionalized nanoparticles; glomerulonephritis; mesangial cells; targeted therapy.
小核酸转染试剂Entranster™-R4000 已有 223 篇已发表文献
同类研究
- Autoimmunity. 2025 Dec;58(1):2576881.doi: 10.1080/08916934.2025.2576881. High glucose promotes O-GlcNAcylation of ACSL4…
- Front Endocrinol (Lausanne). 2025 May 2:16:1556310.doi: 10.3389/fendo.2025.1556310. eCollection 2025. Ameliorative effec…
- Cardiovasc Diabetol. 2024 Dec 21;23(1):452.doi: 10.1186/s12933-024-02545-z. ANXA1-FPR2 axis mitigates the susceptibility…
- Exp Brain Res. 2024 Jan;242(1):33-45.doi: 10.1007/s00221-023-06682-x. Epub 2023 Nov 6. MicroRNA-124 conducts neuroprotec…
- J Physiol. 2024 Jan;602(2):317-332.doi: 10.1113/JP283960. Epub 2023 Dec 28. miR-22-3p in the rostral ventrolateral medul…